Somerset, N.J. – November 26, 2015 — The Catalent Applied Drug Delivery Institute today announced a series of workshops to discuss bioavailability and the need to integrate dose form selection in early phase drug development. The first of these is to be held in collaboration with OBN, the membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, UK, on December 9th, 2015, and subsequent events will be held in other key life science clusters across Europe.
The workshops, which will combine guest speakers including prominent academics, consultants, and technology representatives, alongside Catalent Institute and drug delivery and formulation experts, will give the opportunity for biotech and life science companies to interact with industry experts and discuss some of the developmental challenges faced by research teams with regard to solubility and bioavailability of drug candidates. With increased pressure upon research scientists to deliver compounds for clinical development faster, it is important to ensure candidates have been fully characterized and have the optimal formulation before proceeding to animal studies, in order to increase the chances of their success at later stages of development.
There will also be an opportunity for companies attending the events to discuss active developmental programs in private with Catalent’s science and technology leaders.
The event starts at 8.30 a.m., and will consider the process of molecule assessment, formulation enhancement, and delivery of animal PK study materials, looking at how this approach may help speed onward development of optimal drug delivery forms. The agenda includes a presentation by Alan Harris, PhD and Keith Purdy, PhD of Alacrity Pharma Associates (www.alacritypa.co.uk) who will draw from their considerable wealth of experience within pharmaceutical and biotech research to discuss “Early stage drug development challenges,” before Catalent Institute experts, including Julien Meissonnier, Vice President, Science and Technology and Catalent Institute Board Member, present case studies and technology highlights from Catalent’s wide-ranging and innovative drug delivery technology portfolio.
Further details of upcoming workshops in 2016 will be announced shortly, and to find out more information, or book a place at the Oxford event, visit http://www.eventbrite.com/e/planning-your-journey-before-you-begin-early-dose-form-selection-tickets-19408665842?aff=NEPR
OBN is the Membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. For more information about OBN, please visit www.obn.org.uk
About Catalent Applied Drug Delivery Institute
Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com